Insilico Medicine

In the 2nd quarter of 2021, Deerfield invested in Insilico Medicine through its $255 million Series C preferred financing. Insilico medicine develops software that leverages generative models, reinforces learning, and other modern machine learning techniques for the generation of molecular structures with specific properties. The Company integrates two business models; providing AI-powered drug discovery services and software and developing its own pipeline of preclinical programs.